ArticleJTCVS open2026
New simultaneous lung-kidney allocation policy benefits adult recipients of lung transplant with chronic renal dysfunction.
Article in JTCVS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Objective: The United Network for Organ Sharing defined allocation policies for Simultaneous Lung-Kidney transplantation (SLK) in 2023. However, SLK has rarely been performed, and the benefit for lung transplant candidates remains unclear. We sought to determine the outcomes for lung transplant recipients (LTRs) with pretransplant renal dysfunction and estimate the potential impact of the policy. Methods: Using Organ Procurement and Transplantation Network data, we categorized adult LTRs from 2005 to 2022 by pretransplant renal dysfunction. We then retrospectively applied the 2023 SLK eligibility criteria to identify LTRs with kidney dysfunction who would have been eligible for SLK. Next, we evaluated the outcomes for SLK-eligible LTRs who received SLK or lung transplant using adjusted Cox regression. Results: Among 17,954 LTRs, 1913 (10.7%) had pretransplant renal dysfunction. Applying the new OPTN SLK allocation policy to the retrospective cohort, 292 (16.2%) LTRs would have been eligible for SLK, and 39 LTRs received SLK. SLK recipients had significantly greater pretransplant dialysis use (69% vs 34%, Conclusions: In the historical cohort, a minority of LTRs who were eligible for SLK by contemporary Organ Procurement and Transplantation Network criteria received a multiorgan transplant. However, despite being sicker, recipients of SLK had significantly improved survival compared with candidates eligible for SLK who received lung-only transplants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.